721 related articles for article (PubMed ID: 19804688)
1. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
[TBL] [Abstract][Full Text] [Related]
2. Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma.
Dundar Y; Bagust A; Hounsome J; McLeod C; Boland A; Davis H; Walley T; Dickson R
Health Technol Assess; 2009 Jun; 13 Suppl 1():23-8. PubMed ID: 19567210
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia.
Dretzke J; Barton P; Kaambwa B; Connock M; Uthman O; Bayliss S; Meads C
Health Technol Assess; 2010 Oct; 14(Suppl. 2):19-26. PubMed ID: 21047487
[TBL] [Abstract][Full Text] [Related]
4. Rituximab for the treatment of rheumatoid arthritis.
Bagust A; Boland A; Hockenhull J; Fleeman N; Greenhalgh J; Dundar Y; Proudlove C; Kennedy T; Moots R; Williamson P; Dickson R
Health Technol Assess; 2009 Sep; 13 Suppl 2():23-9. PubMed ID: 19804686
[TBL] [Abstract][Full Text] [Related]
5. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
Ward S; Pilgrim H; Hind D
Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.
Kasteng F; Erlanson M; Hagberg H; Kimby E; Relander T; Lundkvist J
Acta Oncol; 2008; 47(6):1029-36. PubMed ID: 18607857
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
[TBL] [Abstract][Full Text] [Related]
9. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.
Main C; Pitt M; Moxham T; Stein K
Health Technol Assess; 2010 Oct; 14(Suppl. 2):27-32. PubMed ID: 21047488
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib for the treatment of relapsed non-small cell lung cancer.
McLeod C; Bagust A; Boland A; Hockenhull J; Dundar Y; Proudlove C; Davis H; Green J; Macbeth F; Stevenson J; Walley T; Dickson R
Health Technol Assess; 2009 Jun; 13 Suppl 1():41-7. PubMed ID: 19567213
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of sequential treatments for follicular non-hodgkin lymphoma.
Soini EJ; Martikainen JA; Vihervaara V; Mustonen K; Nousiainen T
Clin Ther; 2012 Apr; 34(4):915-925.e2. PubMed ID: 22459623
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal.
Chilcott J; Lloyd Jones M; Wilkinson A
Health Technol Assess; 2009 Jun; 13 Suppl 1():7-13. PubMed ID: 19567208
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation.
Deconinck E; Miadi-Fargier H; Pen CL; Brice P
Pharmacoeconomics; 2010; 28(1):35-46. PubMed ID: 20014875
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Greenhalgh J; Bagust A; Boland A; Fleeman N; McLeod C; Dundar Y; Proudlove C; Shaw R
Health Technol Assess; 2009 Oct; 13 Suppl 3():49-54. PubMed ID: 19846029
[TBL] [Abstract][Full Text] [Related]
16. Infliximab for the treatment of adults with psoriasis.
Loveman E; Turner D; Hartwell D; Cooper K; Clegg A
Health Technol Assess; 2009 Jun; 13 Suppl 1():55-60. PubMed ID: 19567215
[TBL] [Abstract][Full Text] [Related]
17. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
Knight C; Hind D; Brewer N; Abbott V
Health Technol Assess; 2004 Sep; 8(37):iii, ix-xi, 1-82. PubMed ID: 15361313
[TBL] [Abstract][Full Text] [Related]
18. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib for the treatment of multiple myeloma patients.
Green C; Bryant J; Takeda A; Cooper K; Clegg A; Smith A; Stephens M
Health Technol Assess; 2009 Jun; 13 Suppl 1():29-33. PubMed ID: 19567211
[TBL] [Abstract][Full Text] [Related]
20. Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales.
Dewilde S; Woods B; Castaigne JG; Parker C; Dunlop W
J Med Econ; 2014 Feb; 17(2):111-24. PubMed ID: 24308372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]